RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy
Myotonic Dystrophy, Sudden Cardiac Death
About this trial
This is an interventional treatment trial for Myotonic Dystrophy focused on measuring Myotonic dystrophy type 1, Sudden cardiac death, Ventricular tachyarrhythmias, Bradyarrhythmias
Eligibility Criteria
Inclusion Criteria: Patient affected by myotonic dystrophy type I (MD1). Patient willing to provide a signed informed consent. Exclusion Criteria: Age < 18 years old or >70 years old. Ischemic cardiomyopathy Cardiomyopathy due to chronic excess of alcohol consumption (>100 g\day) Congenital heart disease Acquired valvular heart disease Metabolic cardiomyopathy: thyrotoxicosis, hypothyroidism, adrenal cortical insufficiency, pheochromocytoma, acromegaly Familiar storage and infiltrative diseases (hemochromatosis, glycogen storage, Hurler's syndrome, Niemann-Pick disease; primary, secondary, familial and hereditary cardiac amyloidoses) Systemic diseases (connective tissue disorder; sarcoidosis) Peripartum cardiomyopathy
Sites / Locations
- Catholic University of Sacred HeartRecruiting